We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Biogen Inc | NASDAQ:BIIB | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 6.04 | 2.98% | 208.50 | 208.50 | 209.65 | 210.83 | 199.10 | 201.22 | 1,894,099 | 01:00:00 |
From Apr 2019 to Apr 2024
By Matt Grossman
Biogen Inc. on Thursday raised its full-year adjusted-earnings guidance, leaving its revenue forecast unchanged.
The Cambridge, Mass.-based pharmaceutical company said it now expects full-year adjusted earnings of $17.50 to $19 a share, compared with a prior forecast for $17 to $18.50 a share. Analysts surveyed by FactSet had been estimating full-year adjusted earnings of $18.33 a share.
Biogen continues to expect revenue of $10.45 billion to $10.75 billion. Analysts' consensus is for revenue of $10.54 billion.
The company's guidance incorporates an expectation that U.S. regulators will approve aducanumab, a potential treatment for Alzheimer's disease, by June 7. If approved, the drug would launch immediately and contribute modest revenue this year, Biogen said.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
April 22, 2021 07:56 ET (11:56 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Biogen Chart |
1 Month Biogen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
